抗逆转录病毒药物市场按产品类型、给药途径、剂型、最终用户、通路、治疗方案和病患小组划分－2025-2032年全球预测

预计到 2032 年，抗逆转录病毒药物市场规模将达到 421.3 亿美元，年复合成长率为 4.75%。

对影响抗逆转录病毒疗法临床开发和商业性化实施的进展、卫生系统压力和实际优先事项进行策略概述

要了解抗逆转录病毒疗法的现状，需要从两个观点：临床进展和计画实施。过去十年，药物技术的逐步改进使抗逆转录病毒疗法从复杂的多药物联合联合治疗转变为简化的联合治疗和长效製剂，从而重塑了患者的依从性模式和临床疗效。同时，医疗系统和支付方正在调整采购、分发和报销模式，以应对慢性病治疗的需求，同时确保不同患者群体都能获得可及且负担得起的治疗。这种现状需要策略整合，将治疗创新与实际营运结合。

推动抗逆转滤病毒治疗创新和医疗系统采用的重大科学、供应和商业转折点

抗逆转滤病毒治疗领域正经历着变革性的转变，其影响范围不仅限于分子创新，也涵盖给药方案、诊断技术和服务设计等各个面向。在治疗方面，整合酶链转移抑制剂的成熟和联合治疗的策略性应用正在重新定义疗效标准，而对长效注射剂研发的重新关注正在改变患者的依从性预期和治疗路径。这些临床转变与诊断技术日益融入治疗流程同步发生，因此能够更早发现抗药性并制定更精准的治疗方案转换策略。

不断变化的关税制度和贸易措施如何影响抗逆转录病毒疗法的供应链策略、製造地和采购决策

关税和贸易措施的实施将对整个抗逆转录病毒供应链产生连锁反应，从原料药的采购到成品製剂的组装和分销，无一倖免。当进口原料被征收关税时，製造商通常面临更高的单位生产成本，这会影响最终製剂和包装工序的位置决策。为此，一些公司加快了在更靠近终端市场的产能投资，而另一些公司则试图透过与供应商重新谈判合约条款或提高垂直整合度来减轻跨境课税的影响。

提供全面的细分信息，并详细分析产品类型、给药途径、製剂亚型、临床环境、分销渠道、治疗线和病患小组如何影响战略决策。

观点产品类型、给药途径、製剂特性、终端用户环境、分销管道、治疗定位和病患小组角度分析市场，可以发现不同的商业性和临床意义。基于产品类型，每种治疗类别——Ccr5拮抗剂、融合抑制剂、整合酶链转移抑制剂、非核苷类逆转录酶抑制剂、核苷类逆转录酶抑制剂和蛋白酶抑制剂——都具有其独特的抗药性特征、联合用药潜力和安全性考量，这些因素会影响药物选择标准的优先顺序和临床治疗顺序。基于给药途径，口服和肠外给药之间的差异导致了不同的药物支持模式、给药部位要求以及医护人员在註射长效药物时所需的培训。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 长效注射型抗逆转录病毒疗法的出现提高了患者的依从性。
• 增加双药维持治疗的采用，以降低长期毒性风险
• 非专利诺福韦艾拉酚胺製剂的快速普及降低了治疗成本。
• 将数位化药物依从性监测平台整合到爱滋病照护计画中
• 透过扩大儿童抗逆转录病毒药物剂量指引来改善儿童治疗效果
• 用于治疗爱滋病毒的广谱中和抗体疗法的研发仍在继续。
• 监管部门的核准正在推动基于比克替拉韦的单药组合药物的市场应用。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的抗逆转录病毒病毒药物市场

• CCR5拮抗剂
• 融合抑制剂
• 整合酶链转移抑制剂
• 非核苷类逆转录酶抑制剂
• 核苷类逆转录酶抑制剂
• 蛋白酶抑制剂

第九章 依给药途径分類的抗逆转录病毒病毒药物市场

• 口服
• 肠外

第十章抗逆转录病毒药物市场（依剂型划分）

• 注射
  • 静脉注射
  • 皮下注射
• 口服液
  • 解决方案
  • 暂停
• 口服固态剂型
  • 胶囊
  • 药片

抗逆转录病毒病毒药物市场

• 居家医疗
• 医院
• 专科诊所

第十二章抗逆转录病毒药物市场（依分销管道划分）

• 医院药房
• 网路药房
• 零售药房

第十三章 依治疗类别分類的抗逆转录病毒药物市场

• 一线治疗
• 补救性治疗
• 二线治疗

第十四章 按病患小组的抗逆转录病毒病毒药物市场

• 成人版
• 儿童

第十五章 各地区抗逆转录病毒药物市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十六章抗逆转录病毒药物市场（依类别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十七章 各国抗逆转录病毒药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十八章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Gilead Sciences, Inc.
  • ViiV Healthcare ULC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Lupin Limited

The Anti-Retroviral Drugs Market is projected to grow by USD 42.13 billion at a CAGR of 4.75% by 2032.

A strategic overview of anti-retroviral therapeutic advances, health system pressures, and practical priorities shaping clinical development and commercial execution

The introductory landscape for anti-retroviral therapeutics must be read through a dual lens of clinical advancement and programmatic delivery. Over the past decade, incremental pharmacologic refinements have transformed antiretroviral therapy from complex multi-pill regimens to simplified combinations and longer-acting modalities, reshaping adherence paradigms and clinical outcomes. Simultaneously, health systems and payers are recalibrating procurement, distribution, and reimbursement models to manage chronic care demands while preserving access and affordability for diverse patient populations. This context demands a strategic synthesis that aligns therapeutic innovation with operational realities.

This executive summary sets out to provide that synthesis. It outlines the major scientific and commercial inflection points affecting product development, regulatory strategy, and supply chain resilience. The narrative connects pharmacologic class dynamics with practical imperatives around formulation, route of administration, and patient-centered delivery. It also examines policy shifts and trade developments that can materially affect cost structures and manufacturing decisions.

Throughout, the focus remains on providing pragmatic insight for stakeholders who must balance clinical efficacy with scalability and access. Decision-makers will find an integrated view that links therapeutic differentiation to real-world deployment, enabling clearer prioritization of investments in research, manufacturing, and commercial execution.

Key scientific, delivery, and commercial inflection points driving the next phase of anti-retroviral therapeutic innovation and health system adoption

The anti-retroviral field is experiencing transformative shifts that extend beyond molecule-level innovation to include delivery, diagnostics, and service design. On the therapeutic front, the maturation of integrase strand transfer inhibitors and the strategic use of combination regimens have redefined efficacy benchmarks, while renewed R&D focus on long-acting parenteral formulations is changing adherence expectations and care pathways. These clinical shifts are occurring in parallel with diagnostics becoming more integrated into treatment algorithms, enabling earlier detection of resistance and more precise switching strategies.

Operationally, manufacturers and health system planners are adapting to a multipronged distribution reality in which hospital-based supply coexists with home care delivery and specialty clinic administration of injectables. This has accelerated investment in cold chain logistics, novel packaging formats, and patient support services to ensure continuity of therapy. Furthermore, regulatory frameworks are evolving to accommodate accelerated pathways for therapies addressing high unmet need and for new formulations intended to improve adherence.

Market access dynamics are concurrently reshaping product strategies. Pricing pressures and greater demand for cost-effective regimens are prompting differential pricing strategies and greater emphasis on lifecycle management. Partnerships between clinical developers, contract manufacturers, and distribution networks are becoming a dominant approach to manage capital intensity while preserving speed to market. Taken together, these shifts signify a landscape where scientific advancement, delivery innovation, and commercial agility jointly determine competitive positioning.

How evolving tariff regimes and trade measures are reshaping supply chain strategy, manufacturing footprints, and procurement decisions for anti-retroviral therapies

The imposition of tariffs and trade measures can create cascading effects across the anti-retroviral supply chain that extend from active pharmaceutical ingredient procurement to finished-dose assembly and distribution. When duties are applied to imported components, manufacturers commonly face higher unit production costs, which can influence decisions about where to site final formulation and packaging operations. In response, some firms accelerate capacity investments closer to end markets, while others renegotiate supplier terms or pursue vertical integration to reduce exposure to cross-border levies.

Tariff-driven cost pressure also amplifies the importance of supplier diversification and contract structure. Companies that maintain multi-sourced API supply chains or that leverage regional manufacturing partners are better positioned to mitigate the immediate impact of trade measures. Contractual clauses that allow for indexation to input costs or that provide for risk-sharing on tariff changes become more important in negotiations with third-party manufacturers and distributors.

Beyond direct cost implications, tariffs influence inventory strategies and working capital management. Organizations often build strategic buffers to smooth short-term supply disruptions and to provide negotiating leverage, but increased inventory levels carry their own financial and logistical costs. Health systems and procurement agencies may respond by emphasizing local procurement and supporting domestic manufacturing initiatives, which can improve supply security but require multi-year commitments and capital allocation. Ultimately, the cumulative impact of trade policy on anti-retroviral therapeutics underscores the need for flexible manufacturing footprints, robust supplier networks, and proactive commercial strategies that anticipate regulatory and tariff volatility.

Comprehensive segmentation intelligence detailing how product types, administration routes, formulation subtypes, care settings, distribution channels, therapy lines, and patient groups drive strategic decisions

Segmentation analysis reveals distinct commercial and clinical implications when the market is viewed through product types, administration routes, formulation specifics, end user settings, distribution channels, therapy line positioning, and patient groups. Based on product type, therapeutic categories such as Ccr5 antagonists, fusion inhibitors, integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors each carry unique resistance profiles, combination potential, and safety considerations that inform formulary preferences and clinical sequencing decisions. Based on route of administration, the dichotomy between oral and parenteral delivery drives differences in adherence support models, administration site requirements, and training needs for providers administering long-acting injectables.

Based on formulation, the landscape encompasses injectable, oral liquid, and oral solid formats. The injectable class requires attention to both intravenous and subcutaneous administration pathways, with implications for clinic capacity and resource allocation. The oral liquid segment divides into solution and suspension presentations, which are critical for pediatric dosing accuracy and palatability. Oral solid forms split into capsule and tablet presentations, with downstream effects on fixed-dose combination strategies and blister or bottle packaging approaches. Based on end user, deployment patterns vary across home care, hospitals, and specialty clinics, each demanding tailored patient support, cold chain logistics where applicable, and different payer interactions.

Based on distribution channel, the roles of hospital pharmacies, online pharmacies, and retail pharmacies shape access, adherence interventions, and inventory policies, while each channel requires distinct regulatory compliance and dispensing workflows. Based on therapy line, first line, salvage therapy, and second line use cases dictate the clinical evidence required for adoption and determine where differentiated products can demonstrate value. Based on patient group, adult and pediatric populations necessitate investment in age-appropriate formulations, dosing regimens, and clinical safety data. Taken together, these segmentation lenses highlight where commercial and clinical priorities intersect, revealing clear levers for product differentiation, formulary positioning, and targeted service design.

Regional market nuances and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory, manufacturing, and access strategies

Regional dynamics exert a powerful influence on regulatory expectations, payer behavior, manufacturing strategy, and distribution design. In the Americas, market dynamics are characterized by a mature procurement ecosystem, growing emphasis on lifecycle management, and a mix of public and private funding mechanisms that shape reimbursement and access. Manufacturers navigating this region must align clinical development plans with payer evidence requirements and design pricing strategies that reflect both urban tertiary care markets and broader public procurement programs.

Europe, Middle East & Africa presents a heterogeneous set of regulatory frameworks and procurement models. Countries within this combined region vary widely in their reliance on centralized tenders, local manufacturing preferences, and capacity to adopt novel delivery formats such as long-acting injectables. This heterogeneity requires segmented regulatory pathways and often necessitates partnerships with regional distributors or contract manufacturers to ensure market entry is commercially viable and operationally sustainable.

Asia-Pacific features a diverse mix of advanced biotech hubs, generics manufacturing centers, and rapidly evolving health systems that increasingly demand cost-effective regimens while also showing strong uptake of novel technologies where reimbursement pathways exist. Manufacturing proximity in this region can offer supply-chain advantages, but regulatory timelines and local clinical data requirements will influence launch sequencing. Across all regions, alignment with public health initiatives, capacity building for specialty clinic administration, and tailored patient support models remain essential to optimize coverage and adherence outcomes.

Strategic corporate approaches and operational capabilities that industry leaders are prioritizing to accelerate pipeline innovation, secure supply, and strengthen market positioning

Companies operating in the anti-retroviral space are adopting a mixture of innovation, partnership, and operational optimization to secure competitive advantage. Across the sector, investment focus is shifting toward platform investments that support long-acting formulations, fixed-dose combinations, and pediatric-appropriate presentations. Firms are increasingly pursuing licensing deals and co-development agreements to accelerate access to complementary technologies such as novel delivery systems and therapeutic drug monitoring tools.

Operationally, leaders are scaling contract manufacturing relationships to manage capital intensity while maintaining control over quality and supply security. Manufacturing strategies increasingly emphasize modular, geographically distributed facilities that can reduce tariff exposure and shorten delivery timelines to large public procurement programs. At the same time, commercial teams are prioritizing differentiated patient support services and digital adherence interventions to protect regimen persistence and to generate real-world evidence that supports reimbursement discussions.

Strategic M&A and selective in-licensing remain central tactics for companies seeking to broaden portfolios rapidly or to acquire complementary capabilities such as pediatric formulation expertise or biologics development experience. The emphasis on lifecycle management, including reformulations and indication expansions, is shaping R&D portfolios to maximize therapeutic longevity while addressing emerging resistance patterns and unmet patient needs.

Actionable, multi-dimensional recommendations for developers and commercial teams to strengthen clinical differentiation, supply resilience, and payer alignment for anti-retroviral offerings

Industry leaders should adopt a layered strategy that simultaneously addresses clinical differentiation, supply resilience, and payer alignment. First, prioritize development of formulations and delivery systems that address the most significant adherence barriers, including investment in long-acting parenteral options and palatable pediatric liquids, while ensuring that clinical development programs generate comparative effectiveness and safety evidence relevant to payers. Second, strengthen supply chain resilience by diversifying API and finished-dose sourcing, negotiating flexible supplier contracts, and evaluating regional manufacturing hubs to mitigate trade-related disruption and tariff exposure.

Third, engage payers and procurement stakeholders early to co-develop value demonstration frameworks that incorporate patient-reported outcomes and real-world adherence data. Fourth, build scalable patient support infrastructure that integrates digital adherence tools, remote monitoring, and training modules for clinicians administering injectables so that uptake is not constrained by service capacity. Fifth, structure commercial launches with channel-specific plans that reflect the unique needs of hospital pharmacies, online pharmacies, and retail dispensaries, and ensure that distribution partners understand cold chain and handling requirements where relevant.

Finally, pursue collaborative arrangements with public health agencies, non-governmental stakeholders, and clinical networks to expedite guideline inclusion and to support implementation studies. These combined actions will help align product innovation with the practical realities of delivery and reimbursement, improving the probability of sustained adoption across diverse care settings.

A transparent, mixed-methods research approach combining expert interviews, regulatory and clinical data review, and scenario analysis to produce actionable, evidence-based insights

The research methodology underpinning this executive summary integrates qualitative and quantitative approaches to ensure findings are robust and actionable. Primary research included semi-structured interviews with clinicians, procurement officers, manufacturing executives, and payers to capture current practice patterns, procurement constraints, and adoption drivers. Secondary research drew on regulatory filings, clinical trial registries, published peer-reviewed literature, and public health guidance documents to validate clinical trends, safety profiles, and regulatory precedents. Data triangulation was used to reconcile divergent perspectives and to ensure conclusions reflect both clinical practice and commercial reality.

Analytical frameworks included therapeutic class mapping, route-of-administration impact assessment, and segmentation crosswalks that linked formulation and distribution considerations to end user requirements. Scenario analysis was applied to explore the operational implications of trade policy shifts and tariff scenarios, focusing on supply chain adjustments rather than market sizing. Limitations include variability in regional regulatory timelines and the evolving nature of long-acting clinical evidence, which means that ongoing surveillance of clinical outcomes and policy shifts is necessary. Where assumptions were made, they were grounded in contemporary published sources and corroborated by expert interviews to preserve analytical integrity.

Concluding synthesis emphasizing the integration of clinical innovation, operational resilience, and payer-focused evidence to translate therapeutic advances into sustained public health impact

In conclusion, the anti-retroviral landscape is being reshaped by synergistic advances in therapeutics, delivery technologies, and service models, all occurring within a policy environment that can materially affect supply chain economics. Clinical innovation in integrase inhibitors, combination strategies, and long-acting formulations offers clear routes to improved adherence and outcomes, but successful commercialization depends on aligning those innovations with pragmatic considerations such as formulation design, administration capacity, and channel-specific distribution strategies.

Trade policy and tariff dynamics further underscore the need for flexible manufacturing strategies and supplier diversification to protect continuity of supply and to manage cost volatility. Segmentation insights emphasize that product success is contingent on precise alignment with patient groups, therapy lines, and end user capabilities, while regional heterogeneity requires tailored regulatory and commercial approaches. For industry leaders, the pathway to durable market impact lies in integrated planning that couples clinical differentiation with operational resilience and payer-focused evidence generation. This integrated approach will be essential to translate scientific advances into measurable public health gains and sustainable commercial outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of long-acting injectable antiretroviral regimens improving patient adherence
• 5.2. Increasing adoption of two-drug maintenance therapies reducing long-term toxicity risks
• 5.3. Rapid uptake of generic tenofovir alafenamide formulations lowering treatment costs
• 5.4. Integration of digital adherence monitoring platforms into HIV care programs
• 5.5. Expansion of pediatric antiretroviral dosing guidelines to improve child outcomes
• 5.6. Ongoing development of broadly neutralizing antibody therapies for HIV management
• 5.7. Regulatory approvals driving uptake of bictegravir-based single-tablet regimens in markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Retroviral Drugs Market, by Product Type

• 8.1. Ccr5 Antagonists
• 8.2. Fusion Inhibitors
• 8.3. Integrase Strand Transfer Inhibitors
• 8.4. Non-Nucleoside Reverse Transcriptase Inhibitors
• 8.5. Nucleoside Reverse Transcriptase Inhibitors
• 8.6. Protease Inhibitors

9. Anti-Retroviral Drugs Market, by Route Of Administration

• 9.1. Oral
• 9.2. Parenteral

10. Anti-Retroviral Drugs Market, by Formulation

• 10.1. Injectable
  • 10.1.1. Intravenous
  • 10.1.2. Subcutaneous
• 10.2. Oral Liquid
  • 10.2.1. Solution
  • 10.2.2. Suspension
• 10.3. Oral Solid
  • 10.3.1. Capsule
  • 10.3.2. Tablet

11. Anti-Retroviral Drugs Market, by End User

• 11.1. Home Care
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Anti-Retroviral Drugs Market, by Distribution Channel

• 12.1. Hospital Pharmacies
• 12.2. Online Pharmacies
• 12.3. Retail Pharmacies

13. Anti-Retroviral Drugs Market, by Therapy Line

• 13.1. First Line
• 13.2. Salvage Therapy
• 13.3. Second Line

14. Anti-Retroviral Drugs Market, by Patient Group

• 14.1. Adult
• 14.2. Pediatric

15. Anti-Retroviral Drugs Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Anti-Retroviral Drugs Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Anti-Retroviral Drugs Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. Gilead Sciences, Inc.
  • 18.3.2. ViiV Healthcare ULC
  • 18.3.3. Johnson & Johnson
  • 18.3.4. Merck & Co., Inc.
  • 18.3.5. Bristol-Myers Squibb Company
  • 18.3.6. Teva Pharmaceutical Industries Ltd.
  • 18.3.7. Viatris Inc.
  • 18.3.8. Cipla Limited
  • 18.3.9. Aurobindo Pharma Limited
  • 18.3.10. Lupin Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ANTI-RETROVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
• TABLE 209. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 222. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
• TABLE 228. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
• TABLE 230. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 242. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 244. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 246. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 248. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
• TABLE 250. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
• TABLE 305. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 306. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 307. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 308. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 309. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 310. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 311. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 312. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 313. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 314. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 315. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
• TABLE 316. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2